Evidence map›Paper›PMID 36298532›Full record

ArticleVaccines2022

Transient Expression of Flavivirus Structural Proteins in

Naveed Asghar, Wessam Melik, Katrine M Paulsen, Bendikte N Pedersen, Erik G Bø-Granquist, Rose Vikse, Snorre Stuen, Sören Andersson, Åke Strid, Åshild K Andreassen and 1 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Naveed AsgharSchool of Medical Sciences, Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, SE-70362 Örebro, Sweden.ORCID 0000-0003-4442-8503
Wessam MelikSchool of Medical Sciences, Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, SE-70362 Örebro, Sweden.ORCID 0000-0001-9876-6239
Katrine M PaulsenDepartment of Virology, Division for Infection Control, Norwegian Institute of Public Health, N-0213 Oslo, Norway.
Bendikte N PedersenDepartment of Virology, Division for Infection Control, Norwegian Institute of Public Health, N-0213 Oslo, Norway.
Erik G Bø-GranquistDepartment of Production Animal Clinical Sciences, Norwegian University of Life Sciences, N-4325 Sandnes, Norway.ORCID 0000-0002-2740-8562
Rose VikseDepartment of Virology, Division for Infection Control, Norwegian Institute of Public Health, N-0213 Oslo, Norway.ORCID 0000-0002-3706-1603
Snorre StuenDepartment of Production Animal Clinical Sciences, Norwegian University of Life Sciences, N-4325 Sandnes, Norway.
Sören AnderssonDepartment of Public Health Analysis and Data Management, Public Health Agency of Sweden, SE-17165 Solna, Sweden.
Åke StridSchool of Science and Technology, The Life Science Centre, Örebro University, SE-70281 Örebro, Sweden.ORCID 0000-0003-3315-8835
Åshild K AndreassenDepartment of Virology, Division for Infection Control, Norwegian Institute of Public Health, N-0213 Oslo, Norway.ORCID 0000-0002-1614-6747
Magnus JohanssonSchool of Medical Sciences, Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, SE-70362 Örebro, Sweden.ORCID 0000-0003-3962-2141
Norwegian Institute of Public Health · NOÖrebro University · SENorwegian University of Life Sciences · NOPublic Health Agency of Sweden · SE

Funding

Foundation for Knowledge 20190091 and 20200063INTERREG-ØKS ScandTick Innovation 20200422
6 · The paper itself

Abstract

Flaviviruses are a threat to public health and can cause major disease outbreaks. Tick-borne encephalitis (TBE) is caused by a flavivirus, and it is one of the most important causes of viral encephalitis in Europe and is on the rise in Sweden. As there is no antiviral treatment available, vaccination remains the best protective measure against TBE. Currently available TBE vaccines are based on formalin-inactivated virus produced in cell culture. These vaccines must be delivered by intramuscular injection, have a burdensome immunization schedule, and may exhibit vaccine failure in certain populations. This project aimed to develop an edible TBE vaccine to trigger a stronger immune response through oral delivery of viral antigens to mucosal surfaces. We demonstrated successful expression and post-translational processing of flavivirus structural proteins which then self-assembled to form virus-like particles in

Indexed as

flavivirusimmunizationmiceplantprotein expressiontick-borne encephalitis virustobaccotoxicityvaccineVLP

Identifiers

PMID36298532
PMCPMC9610170
OpenAlexW4304190016

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.